YM-155 Hydrochloride: Potent Survivin Inhibitor for Cancer Research

Executive Summary: YM-155 hydrochloride is a highly selective, nanomolar inhibitor of survivin, the smallest member of the inhibitor of apoptosis (IAP) gene family (APExBIO). It exhibits an IC50 of 0.54 nM for survivin suppression, with minimal off-target activity against other IAPs and BCL-2 proteins (Schwartz 2022). YM-155 hydrochloride induces robust anti-proliferative effects and tumor regression in xenograft models of non-small cell lung cancer, melanoma, bladder cancer, aggressive non-Hodgkin lymphoma, and triple-negative breast cancer (survivin.net 16392). It is suitable for advanced apoptosis pathway studies and requires stringent storage and handling protocols. Data-driven evaluation highlights its value in workflow integration and translational oncology.

Biological Rationale

Survivin is the smallest protein within the inhibitor of apoptosis (IAP) family and is encoded by the BIRC5 gene. It is overexpressed in a wide range of human cancers, including lung, breast, and bladder malignancies (Schwartz 2022). Elevated survivin levels are linked to enhanced tumor cell proliferation, reduced apoptosis, and poor prognosis. Targeting the survivin signaling pathway is a validated strategy for inducing cancer cell death and overcoming resistance to chemotherapy. YM-155 hydrochloride was developed as a small-molecule inhibitor to directly and selectively target survivin, addressing the need for specific and potent chemical probes in apoptosis inhibitor research. The compound provides a benchmark for evaluating the IAP pathway in preclinical studies (survivin.net 16377), extending prior work by detailing selectivity and workflow fit.

Mechanism of Action of YM-155 hydrochloride

YM-155 hydrochloride binds to survivin and suppresses its expression at both the mRNA and protein levels. This inhibition disrupts the survivin-dependent signaling that normally blocks apoptosis and promotes mitotic progression. The compound produces a rapid decrease in survivin levels, resulting in increased tumor cell apoptosis and reduced proliferation. YM-155 hydrochloride demonstrates high selectivity for survivin over other IAP family members and BCL-2-related proteins, minimizing off-target effects and cytotoxicity in non-cancerous cells. The molecular mechanism involves interference with transcriptional regulation of BIRC5 and destabilization of survivin protein complexes (Schwartz 2022). These mechanistic insights advance previous summaries by providing detailed pathway specificity, as outlined in this workflow-focused article.

Evidence & Benchmarks

• YM-155 hydrochloride inhibits survivin with an IC50 of 0.54 nM in cell-free enzyme assays, demonstrating nanomolar potency (Schwartz 2022).
• Proliferation is suppressed in a broad spectrum of human cancer cell lines, including non-small cell lung cancer, melanoma, bladder, and breast cancer models (Schwartz 2022).
• YM-155 hydrochloride induces tumor regression in xenograft models, with statistically significant reduction in tumor volume compared to vehicle controls (in vivo, immunodeficient mice, dosage and schedule per study) (Schwartz 2022).
• The compound reduces spontaneous metastasis and prolongs survival in animal models of metastatic triple-negative breast cancer (survivin.net 16392).
• Minimal cytotoxicity is observed in non-tumorigenic cell lines at concentrations effective against cancer cells (Schwartz 2022).

Applications, Limits & Misconceptions

YM-155 hydrochloride is widely used in apoptosis inhibitor research, especially for dissecting the role of survivin in tumor proliferation and resistance. It serves as a reference compound for evaluating new IAP-targeted therapies and is integrated into preclinical workflows for non-small cell lung cancer and triple-negative breast cancer models. The compound's nanomolar potency and selectivity support its use in mechanistic, cellular, and in vivo studies. However, its effects are limited to survivin-dependent pathways, and it is not a pan-IAP inhibitor. Off-target effects in non-survivin-expressing systems are minimal but should be experimentally confirmed in each context.

Common Pitfalls or Misconceptions

• YM-155 hydrochloride is not effective in tumors lacking survivin expression.
• The compound does not inhibit other IAP family members or BCL-2-related proteins at effective doses.
• It should not be used as a diagnostic or therapeutic agent in humans; for research use only.
• Long-term storage of diluted solutions can reduce potency; short-term use of prepared solutions is recommended.
• Results in animal models do not always translate directly to clinical efficacy in humans.

Workflow Integration & Parameters

YM-155 hydrochloride is supplied as a solid with a molecular weight of 398.84 and chemical formula C₂₀H₁₉ClN₄O₃. The product is available from APExBIO as catalog number A3947 (product page). For in vitro studies, it is soluble at ≥19.45 mg/mL in DMSO, ≥4.34 mg/mL in ethanol (with gentle warming and ultrasonic treatment), and ≥48.1 mg/mL in water (with ultrasonic treatment). Solutions should be stored at -20°C and used within a short time frame to preserve stability. Dose-response studies typically begin at nanomolar concentrations and span a range to establish IC50 and maximal effect. Control experiments with non-survivin-expressing cells are recommended to confirm specificity. Detailed workflow guidance, extending prior summaries, is provided in this application-focused article.

Conclusion & Outlook

YM-155 hydrochloride is a benchmark compound in apoptosis inhibitor research, enabling precise dissection of the survivin signaling pathway. Its nanomolar potency, selectivity, and reproducible effects in diverse preclinical models make it a preferred tool for translational oncology workflows. Ongoing research may further refine its applications and elucidate mechanisms of resistance. For authoritative product details and ordering, visit the YM-155 hydrochloride A3947 page. This article expands on previous work by integrating empirical benchmarks, workflow parameters, and practical guidance unavailable in earlier summaries such as this review.